Missouri’s attorney general has told Eli Lilly to stop making hospitals provide claims data to access discounted medicines under the federal 340B programme, according to STAT. The warning reflects a broader trend of state officials challenging pharmaceutical companies’ requirements tied to drug discount access.
This development matters for pharma and healthcare executives because it signals a shift in how states may regulate data collection and discount eligibility. More states could follow Missouri’s lead, increasing compliance risks and operational uncertainty for drugmakers and hospitals alike.
